MCID: EXC002
MIFTS: 42

Exocrine Pancreatic Insufficiency

Categories: Endocrine diseases

Aliases & Classifications for Exocrine Pancreatic Insufficiency

MalaCards integrated aliases for Exocrine Pancreatic Insufficiency:

Name: Exocrine Pancreatic Insufficiency 12 54 43 15 71

Classifications:



External Ids:

Disease Ontology 12 DOID:13316
MeSH 43 D010188
NCIt 49 C84316
SNOMED-CT 67 47367009
ICD10 32 K86.81
UMLS 71 C0267963

Summaries for Exocrine Pancreatic Insufficiency

MalaCards based summary : Exocrine Pancreatic Insufficiency is related to pancreatic agenesis 1 and shwachman-diamond syndrome 1. An important gene associated with Exocrine Pancreatic Insufficiency is COX4I2 (Cytochrome C Oxidase Subunit 4I2), and among its related pathways/superpathways are Ribosome biogenesis in eukaryotes and Pancreatic secretion. The drugs Omeprazole and Choline have been mentioned in the context of this disorder. Affiliated tissues include Pancreas, testes and liver, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 74 Exocrine pancreatic insufficiency (EPI) is the inability to properly digest food due to a lack of... more...

Related Diseases for Exocrine Pancreatic Insufficiency

Diseases related to Exocrine Pancreatic Insufficiency via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 159)
# Related Disease Score Top Affiliating Genes
1 pancreatic agenesis 1 32.4 SPINK1 SCT PNLIP PDX1 CFTR
2 shwachman-diamond syndrome 1 32.3 SBDS ELANE EIF6 EFL1
3 diarrhea 30.9 TNF SCT CFTR CCK
4 irritable bowel syndrome 30.8 TNF CCKAR CCK
5 calvarial hyperostosis 30.7 COX4I2 COX4I1
6 enterokinase deficiency 30.6 SCT CCK
7 pancreas, annular 30.5 SPINK1 SCT
8 maturity-onset diabetes of the young, type 8, with exocrine dysfunction 30.4 PDX1 CEL
9 alcoholic pancreatitis 30.3 SPINK1 SCT CFTR CCK
10 pancreatic steatorrhea 30.2 SCT PNLIP CELA3B CELA1 CCK
11 autoimmune pancreatitis 30.2 TNF CTLA4 CFTR
12 celiac disease 1 30.1 TNF SCT CTLA4 CELA3B CELA1 CCK
13 maturity-onset diabetes of the young 30.0 PTF1A PDX1 CELA3B CEL
14 bronchiectasis 30.0 TNF ELANE CFTR
15 acute pancreatitis 29.6 TNF SPINK1 SCT PNLIP ELANE CFTR
16 pancreatic cancer 29.5 TNF SPINK1 SCT PDX1 CFTR CEL
17 diabetes mellitus 29.0 TNF SPINK1 SCT PTF1A PNLIP PDX1
18 pancreatitis 28.4 UBR1 TNF SPINK1 SCT PTF1A PNLIP
19 exocrine pancreatic insufficiency, dyserythropoietic anemia, and calvarial hyperostosis 13.0
20 johanson-blizzard syndrome 11.9
21 cystic fibrosis 11.8
22 poikiloderma, hereditary fibrosing, with tendon contractures, myopathy, and pulmonary fibrosis 11.6
23 pancreatic agenesis 2 11.4
24 neutropenia, severe congenital, 8, autosomal dominant 11.4
25 pancreas, dorsal, agenesis of 10.5 PTF1A PDX1
26 overgrowth syndrome 10.5
27 functionless pituitary adenoma 10.4 CCKAR CCK
28 acalculous cholecystitis 10.4 CCKAR CCK
29 neutropenia 10.4
30 gastroduodenal crohn's disease 10.4 TNF CCK
31 microscopic polyangiitis 10.4 TNF CTLA4
32 spotted fever rickettsiosis 10.4 TNF CTLA4
33 prss1-related hereditary pancreatitis 10.4 SPINK1 CFTR
34 skin sarcoidosis 10.4 TNF CTLA4
35 dysostosis 10.3
36 nontuberculous mycobacterial lung disease 10.3 TNF CFTR
37 mycobacterium abscessus 10.3 TNF CFTR
38 pustular psoriasis 10.3 TNF ELANE
39 opioid addiction 10.3 CCKAR CCK
40 rickets 10.3
41 alcohol use disorder 10.3
42 duodenal ulcer 10.3 TNF SCT CCK
43 cardiac rupture 10.2 TNF ELANE
44 fibrosis of extraocular muscles, congenital, 1 10.2
45 vitamin b12 deficiency 10.2
46 metaphyseal dysplasia 10.2
47 pancreas disease 10.2
48 lipomatosis 10.2
49 liver cirrhosis 10.2
50 intestinal disease 10.2

Graphical network of the top 20 diseases related to Exocrine Pancreatic Insufficiency:



Diseases related to Exocrine Pancreatic Insufficiency

Symptoms & Phenotypes for Exocrine Pancreatic Insufficiency

GenomeRNAi Phenotypes related to Exocrine Pancreatic Insufficiency according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00106-A-0 9.36 EIF6
2 Decreased viability GR00249-S 9.36 UBR1
3 Decreased viability GR00381-A-1 9.36 CCKAR COX4I2 SCT
4 Decreased viability GR00386-A-1 9.36 CCK CEL COX4I2
5 Decreased viability GR00402-S-2 9.36 CCKAR SCT TNF

MGI Mouse Phenotypes related to Exocrine Pancreatic Insufficiency:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 10.11 CCKAR CEL CFTR CTLA4 PDX1 PNLIP
2 growth/size/body region MP:0005378 10.07 CCKAR CEL CFTR COX4I1 COX4I2 EIF6
3 endocrine/exocrine gland MP:0005379 10.02 CCK CCKAR CFTR CTLA4 PDX1 PTF1A
4 homeostasis/metabolism MP:0005376 10 CCK CCKAR CEL CFTR COX4I2 CTLA4
5 liver/biliary system MP:0005370 9.65 CCKAR CEL CFTR CTLA4 EIF6 PDX1
6 respiratory system MP:0005388 9.17 CCKAR CELA1 CFTR COX4I2 CTLA4 PTF1A

Drugs & Therapeutics for Exocrine Pancreatic Insufficiency

Drugs for Exocrine Pancreatic Insufficiency (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 41)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Omeprazole Approved, Investigational, Vet_approved Phase 2 73590-58-6 4594
2
Choline Approved, Nutraceutical Phase 2 62-49-7 305
3 Bile Acids and Salts Phase 2
4 Omega 3 Fatty Acid Phase 2
5 Lecithin Phase 2
6 Flax Phase 2
7 Soy Bean Phase 2
8 Sunflower Phase 2
9 Antacids Phase 2
10 Proton Pump Inhibitors Phase 2
11 Anti-Ulcer Agents Phase 2
12
Phylloquinone Approved, Investigational Phase 1 84-80-0
13
Menadione Approved, Nutraceutical Phase 1 58-27-5 4055
14 Menaquinone Investigational Phase 1 1182-68-9
15 Micronutrients Phase 1
16 Trace Elements Phase 1
17 Vitamins Phase 1
18 Hemostatics Phase 1
19 Nutrients Phase 1
20 Vitamin K Phase 1
21 naphthoquinone Phase 1
22 Coagulants Phase 1
23 Antifibrinolytic Agents Phase 1
24
carbamide peroxide Approved 124-43-6
25
Saxagliptin Approved 361442-04-8 11243969
26
Repaglinide Approved, Investigational 135062-02-1 65981
27
tannic acid Approved 1401-55-4
28
Benzocaine Approved, Investigational 94-09-7, 1994-09-7 2337
29
Glucagon Approved 16941-32-5
30
gastric inhibitory polypeptide Investigational 100040-31-1
31 Pharmaceutical Solutions
32 Liver Extracts
33 Dipeptidyl-Peptidase IV Inhibitors
34
protease inhibitors
35 HIV Protease Inhibitors
36 Hypoglycemic Agents
37 Incretins
38 Insulin, Globin Zinc
39 insulin
40 Sitagliptin Phosphate
41 Glucagon-Like Peptide 1

Interventional clinical trials:

(show top 50) (show all 90)
# Name Status NCT ID Phase Drugs
1 Evaluation of the Digestive and Metabolic Utilisation of Dietary Protein in Patients With Chronic Pancreatitis Completed NCT00957151 Phase 4 Creon
2 An Open-Label Study Evaluating the Efficacy and Safety of Liprotamase in Subjects With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis Completed NCT02823964 Phase 4 Liprotamase
3 A Multicenter, Open-Label, Safety Extension of Study PR-011 Titled: A Multicenter, Randomized, Open-Label, Crossover Study to Evaluate the Mode of Administration and Safety of EUR-1008 in Infants 1 to 12 Months of Age With Exocrine Pancreatic Insufficiency (EPI) Associated With Cystic Fibrosis (CF) Completed NCT01131507 Phase 4 EUR-1008 (APT-1008)
4 An Open-label, Multicenter, Randomized, Cross-over Study to Compare the Safety and Efficacy of PANZYTRAT® 25,000 to KREON® 25,000 in the Control of Steatorrhea in Subjects Aged 7 Years and Older With Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (EPI) Completed NCT01327703 Phase 4 Panzytrat® 25,000;Kreon® 25,000
5 A Multicenter, Randomized, Open-Label, Crossover Study to Evaluate the Mode of Administration and Safety of EUR-1008 in Infants 1 to 12 Months of Age With Exocrine Pancreatic Insufficiency (EPI) Associated With Cystic Fibrosis (CF) Completed NCT01100606 Phase 4 EUR-1008 (APT-1008);EUR-1008 (APT-1008)
6 One Week Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multi-Center Study With Creon® 25000 Minimicrospheres™ in Subjects With Pancreatic Exocrine Insufficiency After Pancreatic Surgery, Followed by an Open-Label Long-Term Extension of 1 Year Completed NCT00535756 Phase 4 Creon;Placebo
7 Enzyme Substitution in Exocrine Pancreatic Insufficiency; Self Administration Against a Fixed Dose Regimen Completed NCT01430234 Phase 4 Panzytrat 25.000 FIP-E units of Lipase
8 MALABSORPTION BLOOD TEST: Toward a Novel Approach to Quantify Steatorrhea Completed NCT00572975 Phase 4
9 Creon (Pancrelipase) Therapy for Subjects With Exocrine Pancreatic Insufficiency (EPI) Due to Pancreatic Cancer: A Double-blind, Randomized, Parallel Design With 2 Dose Cohorts of Pancrelipase in Resected Pancreatic Cancer Subjects and an Open-label Single Dose Cohort in Non-resected Pancreatic Cancer Subjects Recruiting NCT03859869 Phase 4 Pancrelipase;Placebo
10 A Phase 4 Study to Compare US Marketed Creon Drug Product With Drug Product Manufactured With a Modernized Process at an Alternate Manufacturing Site, in Subjects With Exocrine Pancreatic Insufficiency (EPI) Due to Cystic Fibrosis Recruiting NCT03924947 Phase 4 Pancrelipase
11 H.O.P.E. Healing Optimization Through Preoperative Engagement: A Prospective Single Cohort Study to Evaluate the Effect of a Prehabilitation Program on Preoperative Outcomes in Upper GI Surgical Oncology Patients Enrolling by invitation NCT03642093 Phase 4
12 A Phase 4 Open-Label Single-Arm Study To Evaluate The Use Of CREON In Subjects With EPI Due To Etiologies Other Than Cystic Fibrosis, Chronic Pancreatitis, Pancreatectomy, Or Pancreatic Cancer Not yet recruiting NCT04315311 Phase 4 CREON
13 Intraduodenal Aspiration Study to Assess the Bioavailability of Oral Pancrecarb® Compared to Placebo Control in Patients With Pancreatic Insufficiency Terminated NCT00744250 Phase 4 Pancrelipase
14 Randomized, Double Blind, Placebo-controlled Trial of Creon in Patients With Low Faecal Pancreatic Elastase Terminated NCT01865695 Phase 4 Creon
15 A Double-blind, Randomized, Multi-center, Placebo-controlled, Parallel-group Study to Assess the Effect of Creon® on Pancreatic Exocrine Insufficiency in Subjects With Diabetes Mellitus Type 2 Withdrawn NCT02009410 Phase 4 Creon;Creon 25000 matching Placebo
16 Exocrine Pancreatic Insufficiency in Pancreatic Cancer: Evaluating the Need and Efficacy of Pancreatic Enzyme Replacement Therapy Withdrawn NCT01401387 Phase 4
17 A Phase 3, Randomized, Open-Label, Assessor-Blind, Non-Inferiority, Active-Comparator Study Evaluating the Efficacy and Safety of Liprotamase in Subjects With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency Unknown status NCT03051490 Phase 3 Liprotamase;porcine PERT
18 Clinical Non-Inferiority of Pancreatic Enzymes (Norzyme ® - Bergamo) Compared To Creon ® (Solvay Pharmaceutical) in Patients With Exocrine Pancreatic Insufficiency Unknown status NCT01012908 Phase 2, Phase 3
19 An Open-Label Clinical Study Evaluating the Long-Term Safety of ALTU-135 for the Treatment of Patients With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency Completed NCT00449904 Phase 3 Liprotamase
20 A Phase 3, Open-Label Study Evaluating the Efficacy and Safety of Liprotamase in Subjects With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency Completed NCT02734810 Phase 3 Liprotamase Powder for Oral Solution
21 A Randomised, Double-Blind, Active-Controlled, Two-Treatment, Crossover, Multinational, Multicentre Study to Compare Two Pancreatic Enzyme Products in the Treatment of Exocrine Pancreatic Insufficiency in Subjects With Cystic Fibrosis Completed NCT01641393 Phase 3 EUR-1008 25,000 Units;Kreon 25,000 Units
22 A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Study Evaluating the Efficacy and Safety of ALTU-135 Treatment in Patients With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency Completed NCT00449878 Phase 3 Liprotamase;Placebo
23 A Study to Investigate the Effect of Delayed Release Pancrelipase on Maldigestion in Patients With Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis and Pancreatectomy Completed NCT00414908 Phase 3 Pancrelipase delayed release capsule;Placebo Comparator
24 An Open-Label Study to Evaluate the Efficacy and Safety of Pancreatic Enzyme Product (PEP) Microtabs in Pediatric Patients With Cystic Fibrosis and Exocrine Pancreatic Insufficiency Completed NCT00981214 Phase 3 EUR-1008 (APT-1008)
25 A Double-blind, Placebo-controlled, Parallel-group, Comparative Study to Confirm the Safety and Efficacy of Oral 1.5 g/Day and 3.0 g/Day of SA-001 in Patients With Pancreatic Exocrine Insufficiency Caused by Chronic Pancreatitis or by Pancreatectomy Completed NCT00400842 Phase 3 SA-001;SA-001;Placebo
26 A Phase 3, Randomized, Open-Label, Assessor-Blind, Noninferiority, Active-Comparator Study Evaluating the Efficacy and Safety of Liprotamase in Subjects With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency Completed NCT02279498 Phase 3 Liprotamase;porcine (pig) PERT
27 A Multicenter, Randomized, Double-Blind, Crossover Study to Compare the Safety and Efficacy of Ultrase® MT20 to Placebo for the Correction of Steatorrhea in Patients With Cystic Fibrosis (CF) Completed NCT00408317 Phase 3 Ultrase® MT20;Placebo
28 An Open Label, Multi-center, Study to Assess the Safety and Tolerability of Pancrelipase Delayed Release Capsules in Infants and Children Less Than 7 Years of Age With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis Completed NCT00775528 Phase 3 Pancrelipase Delayed Release
29 A Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled, Phase III Study to Assess the Safety and Efficacy of Viokase® 16 for the Correction of Steatorrhea in Patients With Exocrine Pancreatic Insufficiency Completed NCT00559364 Phase 3 Viokase® 16;Placebo;Proton pump inhibitor (PPI);Omeprazole
30 A Double-blind, Randomized, Multi-center, Placebo-controlled, Cross-over Study to Assess the Efficacy and Safety of Pancrelipase Delayed Release 12,000 Unit Capsules in Subjects Aged 7 - 11 With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis Completed NCT00690820 Phase 3 Pancrelipase Delayed Release;Placebo Comparator
31 A Double-blind, Randomized, Multicenter, Cross-over Study to Compare the Effect of Creon N and Creon® on Fat Digestion in Subjects ≥ 12 Years of Age With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis Completed NCT02137382 Phase 3 Creon®;Creon N
32 A Randomized Double-blind (Withdrawal) Phase 3 Study to Evaluate the Efficacy and Tolerability of Pancrelipase MT Capsules Compared With Placebo in the Treatment of Subjects With Cystic Fibrosis-dependent Exocrine Pancreatic Insufficiency Completed NCT00662675 Phase 3 Pancrease MT 10.5, or MT 21;Placebo for Pancrease MT 10.5 or MT 21
33 A One-year Open-label Study to Assess the Safety of Oral Long-term Use of SA-001 in Patients With Pancreatic Exocrine Insufficiency Caused by Chronic Pancreatitis or by Pancreatectomy Completed NCT00401076 Phase 3 SA-001
34 A Randomized, Double-Blind, Placebo-Controlled, Two-Treatment, Crossover Study to Evaluate the Safety and Efficacy of Eurand Pancreatic Enzyme Product (PEP) in Patients With Cystic Fibrosis and Exocrine Pancreatic Insufficiency Completed NCT00297167 Phase 3 EUR-1008 (APT-1008);Placebo;Placebo;EUR-1008 (APT-1008)
35 A One Week Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-Center Study With Creon 40,000 MMS in Subjects With Pancreatic Exocrine Insufficiency Due to Chronic Pancreatitis, Followed by an Open-Label Long-Term Extension Completed NCT00705978 Phase 3 Pancreatin;Placebo
36 A Randomized, Double-Blind, Dose Response-Control, Crossover Study to Evaluate the Safety and Efficacy of Two Doses of EUR-1008 in Chronic Pancreatitis (CP) Patients With Exocrine Pancreatic Insufficiency (EPI) Completed NCT00788593 Phase 3 Placebo;EUR-1008 (APT-1008) High Dose;EUR-1008 (APT-1008) Low Dose
37 A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Crossover Study to Evaluate the Effectiveness and Safety of PANCRECARB® MS-16 (Pancrelipase) in Reducing Steatorrhea in Children and Adults With Cystic Fibrosis Completed NCT00432861 Phase 3 PANCRECARB® (pancrelipase);Placebo
38 An Open Label, Multicenter Study Evaluating Safety and Tolerability of Creon Micro in Pediatric Subjects From at Least One Month to Less Than Four Years of Age With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis Completed NCT01747330 Phase 3 Pancreatin
39 Efficacy and Safety of Ultrase MT12 in the Control of Steatorrhea in Cystic Fibrosis (CF) and Pancreatic Insufficient (PI) Children Aged 2 to 6 Years Old Completed NCT00880100 Phase 3 Ultrase® MT12
40 Efficacy and Safety of Ultrase® MT20 in Improving the Coefficient of Fat Absorption (CFA%) in Children With Cystic Fibrosis (CF) and Pancreatic Insufficiency (PI) Completed NCT00513682 Phase 3 Ultrase® MT20
41 Open-label, Multicenter, Randomized, Cross-Over, Equivalence Study to Compare the Efficacy and Safety of Two Strengths of Pancreatin Enteric-Coated Capsules in Pancreatic Exocrine Insufficiency in Chinese Subjects Recruiting NCT03450772 Phase 3 Creon® 25000;Creon® 10000
42 Recurrent Abdominal Pain and Exocrine Pancreatic Insufficiency Not yet recruiting NCT04231279 Phase 3 synthetic human secretin
43 An Open-Label Clinical Study Evaluating the Long Term Safety of ALTU-135 in the Treatment of Patients With Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis or Pancreatectomy Terminated NCT00500084 Phase 3 Liprotamase
44 A Phase 2, Open-Label, Multicenter, 2x2 Crossover Trial to Assess the Safety and Efficacy of MS1819-SD in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis Completed NCT03746483 Phase 2 MS1819-SD;Porcine PERT
45 A Phase 2, Randomized, Double Blind, Parallel Dose Ranging Study of Oral TheraCLEC™ - Total in Cystic Fibrosis Subjects With Exocrine Pancreatic Insufficiency Completed NCT00095732 Phase 2 Liprotamase;Placebo
46 A Randomized, Double-blind, Multicenter, Two-period Crossover Study to Assess the Efficacy and Tolerability of NM-BL (Burlulipase) in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis Completed NCT01710644 Phase 1, Phase 2 Burlulipase;Placebo (Caramel in sterile water)
47 A Multicentre Open-label Phase IIa Study With Escalating Dose of MS1819- SD, to Investigate the Efficacy and Safety of a Yarrowia Lipolytica Lipase Preparation for the Compensation of Exocrine Pancreatic Insufficiency Caused by Chronic Pancreatitis and/or Distal Pancreatectomy Completed NCT03481803 Phase 2 MS1819-SD
48 A Phase II, Multicenter, Parallel-Group, Active-Controlled, Randomized, Double-blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Different Doses of Creon IR in Subjects With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis Completed NCT02415959 Phase 2 Creon IR;Creon® (DR/GR)
49 An Open-Label Cross-over Study to Evaluate the Intraduodenal Delivery of Lipase, Protease and Amylase From Administration of VIOKASE16 in Chronic Pancreatitis Subjects With Exocrine Pancreatic Insufficiency (EPI). Completed NCT00559052 Phase 2 VIOKASE 16
50 An Open Label, Exploratory Study on the Effect of rhBSSL on the Fat Absorption in Patients With Cystic Fibrosis and Pancreatic Insufficiency Completed NCT00743483 Phase 2 rhBSSL

Search NIH Clinical Center for Exocrine Pancreatic Insufficiency

Cochrane evidence based reviews: exocrine pancreatic insufficiency

Genetic Tests for Exocrine Pancreatic Insufficiency

Anatomical Context for Exocrine Pancreatic Insufficiency

MalaCards organs/tissues related to Exocrine Pancreatic Insufficiency:

40
Testes, Pancreas, Liver, Bone, Bone Marrow, Small Intestine, Kidney
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Exocrine Pancreatic Insufficiency:
# Tissue Anatomical CompartmentCell Relevance
1 Pancreas Pancreatic Acini Acinar Cells Affected by disease, potential therapeutic candidate

Publications for Exocrine Pancreatic Insufficiency

Articles related to Exocrine Pancreatic Insufficiency:

(show top 50) (show all 1167)
# Title Authors PMID Year
1
13C-labeled mixed triglyceride breath test (13C MTG-BT) in healthy children and children with cystic fibrosis (CF) under pancreatic enzyme replacement therapy (PERT): a pilot study. 54 61
18817766 2008
2
Exocrine pancreatic insufficiency in the Eurasian dog breed--inheritance and exclusion of two candidate genes. 61 54
17302791 2007
3
Is exocrine pancreatic insufficiency in adult coeliac disease a cause of persisting symptoms? 54 61
17269988 2007
4
Does secretin-stimulated MRCP predict exocrine pancreatic insufficiency?: A comparison with noninvasive exocrine pancreatic function tests. 61 54
17016144 2006
5
Homozygous (TG)11 allele in intron 8 of the cystic fibrosis transmembrane conductance regulator (CFTR) gene has a protective role against bicarbonate decrease in pure pancreatic juice among Japanese male alcoholics. 54 61
15645646 2004
6
[New fecal markers: recent developments and perspectives]. 61 54
15550893 2004
7
Low fecal elastase: potentially related to transient small bowel damage resulting from enteric pathogens. 61 54
12604981 2003
8
Faecal elastase 1 concentration is a marker of duodenal enteropathy. 61 54
11806885 2002
9
[Maldigestion during chronic pancreatitis]. 54 61
11458612 2001
10
Comparison of fecal elastase-1 determination with the secretin-cholecystokinin test in patients with cystic fibrosis. 54 61
10192202 1999
11
Comparative clinical evaluation of the 13C-mixed triglyceride breath test as an indirect pancreatic function test. 61 54
9548629 1998
12
13C-starch breath test--comparative clinical evaluation of an indirect pancreatic function test. 61 54
9106982 1997
13
Intraduodenal free fatty acids rather than triglycerides are responsible for the release of CCK in humans. 54 61
8981511 1997
14
Immunoreactive elastase I: clinical evaluation of a new noninvasive test of pancreatic function. 54 61
8595714 1996
15
Maldigestion after total gastrectomy is associated with pancreatic insufficiency. 54 61
8607504 1996
16
[Measurement of fecal elastase 1 by immunoreactivity: a new indirect test of the pancreatic function]. 61 54
8761139 1996
17
Lack of accuracy of plasma alpha-amino nitrogen profiles as an indicator of exocrine pancreatic function both after continuous and bolus stimulation of the pancreas with secretin and cholecystokinin-pancreozymin. 54 61
7871858 1994
18
Adenovirus-mediated transfer of human lipase complementary DNA to the gallbladder. 61 54
8194711 1994
19
[The diagnostic value of the amino acid absorption test in detection of a disorder of exocrine pancreatic function]. 54 61
1636270 1992
20
Fecal isoamylase activity in patients with pancreatic diseases. 54 61
1704633 1991
21
Nutritional deficiency post esophageal and gastric cancer surgery: A quality improvement study. 61
32566222 2020
22
Lessons learnt from MyCyFAPP Project: Effect of cystic fibrosis factors and inherent-to-food properties on lipid digestion in foods. 61
32466896 2020
23
Clinical Characteristics and Long-term Outcomes of Children With Fibrosing Pancreatitis. 61
32443035 2020
24
EUS pancreatic function testing and dynamic pancreatic duct evaluation for the diagnosis of exocrine pancreatic insufficiency and chronic pancreatitis. 61
32562609 2020
25
Editorial: management of exocrine pancreatic insufficiency remains a challenge-can we do better? 61
32424918 2020
26
The Applicability of a Checklist for the Diagnosis and Treatment of Exocrine Pancreatic Insufficiency: Results of the Italian Exocrine Pancreatic Insufficiency Registry. 61
32541636 2020
27
Effectivity of Pancreatic Enzyme Replacement Therapy in Malnourished Children. 61
32443036 2020
28
Laparoscopic Frey's Procedure for Chronic Pancreatitis in a Japanese Patient. 61
32541646 2020
29
Maldigestion Versus Malabsorption in the Elderly. 61
32500383 2020
30
Endoscopic treatment with transmural drainage and necrosectomy for walled-off necrosis provides favourable long-term outcomes on pancreatic function. 61
32326877 2020
31
Multicentric Italian survey on daily practice for autoimmune pancreatitis: Clinical data, diagnosis, treatment, and evolution toward pancreatic insufficiency. 61
32397913 2020
32
ATP6AP1-CDG: Follow-up and female phenotype. 61
32395412 2020
33
The use of pancreatic enzyme replacement therapy in patients with a diagnosis of chronic pancreatitis and pancreatic cancer in the US is infrequent and inconsistent. 61
32249970 2020
34
Patient reported exposure to smoking and alcohol abuse are associated with pain and other complications in patients with chronic pancreatitis. 61
32507681 2020
35
Clinical Characteristics and Long-term Outcomes of Children With Fibrosing Pancreatitis. 61
32304545 2020
36
Two cases of agenesis of the dorsal pancreas and a review of the literature. 61
32252649 2020
37
Restoration of exocrine pancreatic function in older children with cystic fibrosis on ivacaftor. 61
32386958 2020
38
Chronic Pancreatitis and Bone Disease. 61
31558406 2020
39
Severe forms of Johanson-Blizzard syndrome caused by two novel compound heterozygous variants in UBR1: Clinical manifestations, imaging findings and molecular genetics. 61
31980351 2020
40
Exocrine Pancreatic Insufficiency in Type 1 and Type 2 Diabetes. 61
32239341 2020
41
Exocrine pancreatic insufficiency: Can this be the cause of your patient's GI symptoms? 61
32068705 2020
42
Diagnostic and Therapeutic Management of Post-Gastric Bypass Chronic Diarrhea: a Systematic Review. 61
31902043 2020
43
The baseline nutritional status assessed by MUST score has a low accuracy in predicting the risk of hospitalization during follow-up in patients with chronic pancreatitis: A cohort study. 61
31926768 2020
44
Superiority of endoscopic interventions over minimally invasive surgery for infected necrotizing pancreatitis: meta-analysis of randomized trials. 61
31220368 2020
45
ACG Clinical Guideline: Chronic Pancreatitis. 61
32022720 2020
46
Broadening the phenotypic spectrum of Pearson syndrome: Five new cases and a review of the literature. 61
31825167 2020
47
Inflammatory bowel disease in Shwachman-Diamond syndrome; is there an association? 61
31196706 2020
48
Association of multiple patient and disease characteristics with the presence and type of pain in chronic pancreatitis. 61
31314128 2020
49
Exocrine pancreatic insufficiency in distal pancreatectomy: incidence and risk factors. 61
31327560 2020
50
Characterization of all the lipolytic activities in pancreatin and comparison with porcine and human pancreatic juices. 61
31288050 2020

Variations for Exocrine Pancreatic Insufficiency

Expression for Exocrine Pancreatic Insufficiency

Search GEO for disease gene expression data for Exocrine Pancreatic Insufficiency.

Pathways for Exocrine Pancreatic Insufficiency

Pathways related to Exocrine Pancreatic Insufficiency according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.38 SBDS EIF6 EFL1
2 11.18 SCT PNLIP CFTR CELA3B CEL CCKAR
3 9.8 SCT CCK

GO Terms for Exocrine Pancreatic Insufficiency

Cellular components related to Exocrine Pancreatic Insufficiency according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.28 TNF SPINK1 SCT PNLIP ELANE CELA3B
2 mitochondrial respiratory chain complex IV GO:0005751 8.96 COX4I2 COX4I1

Biological processes related to Exocrine Pancreatic Insufficiency according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ribosome biogenesis GO:0042254 9.58 SBDS EIF6 EFL1
2 embryonic digestive tract development GO:0048566 9.46 TNF SCT
3 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.43 TNF ELANE
4 intestinal cholesterol absorption GO:0030299 9.37 PNLIP CEL
5 generation of precursor metabolites and energy GO:0006091 9.33 PDX1 COX4I2 COX4I1
6 lipid digestion GO:0044241 9.32 PNLIP CEL
7 pancreatic juice secretion GO:0030157 9.26 SCT CEL
8 exocrine pancreas development GO:0031017 9.13 PTF1A PDX1 CELA1
9 mature ribosome assembly GO:0042256 8.8 SBDS EIF6 EFL1

Molecular functions related to Exocrine Pancreatic Insufficiency according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ribosome binding GO:0043022 8.8 SBDS EIF6 EFL1

Sources for Exocrine Pancreatic Insufficiency

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....